Despite a surge in Lee's Pharmaceutical's stock, a modest P/...
Despite a surge in Lee's Pharmaceutical's stock, a modest P/S ratio remains due to expected weak growth. Declining revenue fuels shareholder pessimism and the firm needs a significant turnaround to justify a higher P/S ratio.
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more